AT-014 (Asieris Pharmaceuticals)

AT-014 is a preclinical-stage drug candidate being developed by Asieris Pharmaceuticals for the treatment of urological tumors (also referred to as urogenital system tumors). The drug was discovered using Asieris' proprietary Target-based AI-Driven Drug Discovery (TAIDD) platform, which integrates artificial intelligence technology throughout the drug discovery process to streamline identification and optimization. As of 2024, Asieris Pharmaceuticals has not publicly disclosed the specific biological target, active ingredient, or modality of AT-014, although the company maintains global development rights for the candidate.